These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15462281)

  • 1. Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.
    Jirathitikal V; Bourinbaiar AS
    Acta Virol; 2004; 48(2):73-8. PubMed ID: 15462281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration.
    Jirathitikal V; Metadilogkul O; Bourinbaiar AS
    Eur J Clin Nutr; 2004 Jan; 58(1):110-5. PubMed ID: 14679375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV.
    Bourinbaiar AS; Jirathitikal V; Metadilogkul O; Sooksathan P; Paiboon P; Aemsri S; Prapai P; Chaodon K
    J Clin Virol; 2004 Dec; 31 Suppl 1():S55-62. PubMed ID: 15567095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease.
    Jirathitikal V; Bourinbaiar AS
    HIV Clin Trials; 2002; 3(1):21-6. PubMed ID: 11819182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
    Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
    Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".
    MacGregor RR; Boyer JD; Ugen KE; Tebas P; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; Weiner DB
    Vaccine; 2005 Mar; 23(17-18):2066-73. PubMed ID: 15755572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged survival of end-stage AIDS patients immunized with therapeutic HIV vaccine V-1 Immunitor.
    Metadilogkul O; Jirathitikal V; Bourinbaiar AS
    Biomed Pharmacother; 2005 Sep; 59(8):469-73. PubMed ID: 16126364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
    J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to hepatitis A vaccine in HIV-positive patients.
    Weissman S; Feucht C; Moore BA
    J Viral Hepat; 2006 Feb; 13(2):81-6. PubMed ID: 16436125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
    Schooley RT; Spino C; Kuritzkes D; Walker BD; Valentine FA; Hirsch MS; Cooney E; Friedland G; Kundu S; Merigan TC; McElrath MJ; Collier A; Plaeger S; Mitsuyasu R; Kahn J; Haslett P; Uherova P; deGruttola V; Chiu S; Zhang B; Jones G; Bell D; Ketter N; Twadell T; Chernoff D; Rosandich M
    J Infect Dis; 2000 Nov; 182(5):1357-64. PubMed ID: 11023459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].
    Qiu ZF; Li TS; Ruan GR; Han Y; Xie J; Zuo LY; Li YL; Wang AX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):386-90. PubMed ID: 16900640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.